Who
Keith Katkin
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions; Director, Syndax Pharmaceuticals; Director, Eledon Pharmaceuticals; Director, Rigel Pharmaceuticals; PEO;CEO/Urovant Sciences, Inc., Urovant Sciences; Director, Carbylan Therapeutics; President and CEO, Avanir Pharmaceuticals.
In numbers
- Trades disclosed
- 202
- Buys
- 4
- Sells
- 34
- Bought
- $146K
- Sold
- $14.2M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 25 May 2006
- Last trade
- 30 Apr 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 3 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $128K15,481 at $8.28 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $128K15,481 at $8.28 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,575 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,575 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,575 at $0.00 | filing |
| 10 Jan 2026filed 16 Jan 2026 | ELDN Eledon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,575 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $49K7,844 at $6.30 | filing |
| 19 May 2025filed 19 May 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $91K10,000 at $9.11 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,175 at $0.00 | filing |
| 10 Jan 2025filed 13 Jan 2025 | ELDN Eledon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,575 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)EBS · dailypolitical.com · 6 Oct 2026Critical Analysis: Coherus Oncology (NASDAQ:CHRS) and Emergent Biosolutions (NYSE:EBS)EBS · themarketsdaily.com · 5 Oct 2026
0 headlines in the last 90 days name Keith Katkin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.